

HHCS Human Hepatocytes Cryopreserved for Suspension Assays
Cell Specification – Certificate of Analysis (CoA)

Lot HH160222

Batch Release: July 03, 2023

Donor data

Species: Human

Gender: female

Age: 59 years

Diagnosis: CCC (cholangiocellular carcinoma)
HCC (hepatocellular carcinoma)
Medical History: Hypertension
Therapy: segment resection liver S6
Serology: HAV, HBV, HCV, HIV 1/2: negative

Medication: Amlodipin, Omeprazol, Cymbalta,
Keltican (Vit. B), Estrifam
1 mg/ 2 mg, Relvar Spray
Others: testicular feminization syndrome, XY-
syndrome

Cryopreservation and Thawing

Cryopreservation:

Date: Feb 22, 2016
Amount per vial: 9.8×10^6 cells

Thawing:

Post-thaw viability: 91.3 %
Post-thaw yield per vial: 2.5×10^6 cells
Recovery: 25.5 %

Suspension culture

Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5×10^6 cells in 0.5 ml HPM-Cryo):

Time (h)	0	1	2	3
Viability (%)	91.3	74.5	62.1	51.7

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.

Store at -150 °C or in the vapour phase of LN₂

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: M. Thiede

Verified by: K.Damrau